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Our intention was to evaluate the relationships between the A–B neuropsychological assessment schedule (ABNAS) as a
measure of patient-perceived cognitive effects of antiepileptic drugs (AEDs) and the results of neuropsychological tests. The
measure was developed specifically to assess patient-perceived cognitive effects of AED treatment. Evidence of its reliability
and validity has been previously documented. In this study 96 patients were included using stratified inclusion-criteria to
guarantee variability of performance: 55 patients were included from a ‘low risk condition’ with respect to possible cognitive
effect (i.e. monotherapy carbamazepine within a dose range of 600–1200 mg/day) and 41 patients were included from a
‘high risk condition’ (i.e. polytherapy of three or two AEDs including either phenytoin, phenobarbitone or a benzodiazepine;
treatment with topiramate with a titration speed using 50 mg or higher increments per week and within the first 6 months of
treatment). All patients were prospectively assessed using the ABNAS and five neuropsychological tests (all part of the FePsy
test system) with proven sensitivity of cognitive effects of antiepileptics: three tasks using reaction-time to measure speed
(‘simple (visual) reaction-time measurement’, ‘the binary choice reaction test’ and ‘the computerized visual searching task’);
one test measuring motor speed (‘the finger tapping task’); and a memory test (‘recognition of words’). The three reaction-
time tasks and the finger tapping test were significantly correlated with the ABNAS-score with correlations ranging from 0.22
to 0.35. The highest correlation was with ‘simple (visual) reaction-time measurement’ (0.35). Discriminant analysis showed
that with the neuropsychological tests 61.5% of the patients were correctly identified as having high/low ABNAS-scores. The
ABNAS underestimated impairment in 17.8% of the patients (= low ABNAS-score but impairment on the neuropsychological
tests). The present study contributes to the already existing evidence of validity of the ABNAS as a screening instrument for
clinical practice as the relationship between the ABNAS-score and results of neuropsychological tests can help to identify who
is at risk and needs further referral for neuropsychological assessment. Moreover the correlation between ABNAS-score and
those neuropsychological tests that are sensitive for drug-effects may provide a sensitive instrument in early drug-development
phases while keeping the burden on financial and time resources to a minimum.
c© 2002 Published by Elsevier Science Ltd on behalf of BEA Trading Ltd.
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INTRODUCTION
The evaluation of adverse cognitive effects of
antiepileptic drugs (AEDs) has gained prominence in
recent years20; as has the incorporation of the patient’s
perspective in treatment and research protocols. The
importance of developing an instrument with sufficient
reliability, validity, and sensitivity to reflect patient-
perceived drug-related cognitive impairments, while
keeping the burden on financial and time resources to
a minimum, was clear. The development of such an
instrument—‘The AB neuropsychological assessment
schedule’ (ABNAS; originally the A–B neurotoxicity
scale)—has been undertaken by our group since 1993.
1059–1311/02/$22.00/0 c© 2002 Published by Elsevier Science Ltd on behalf of BEA Trading Ltd.
232 A. P. Aldenkamp et al.
The first step analysed clinical validity in a random-
ized, double-blind, parallel-group volunteer study4
comparing three groups: 10 mg temazepam, 20 mg
temazepam, and placebo. Significant differences were
found in ABNAS-scores between placebo and the two
temazepam groups indicating that adverse cognitive
effects of drugs could be detected using this scale4.
In addition, it became clear that the ABNAS-score
represents a global report, i.e. revealing cognitive
impairment irrespective of the type or severity of
the impairments. It was therefore characterized as a
screening instrument, identifying who is at risk of
drug-induced cognitive impairment and thus providing
a tool for referral for further neuropsychological
evaluation.
Further validation of the instrument was undertaken
in 19976, with a specific focus on construct validity
and reliability of the scale in 189 patients with chronic
epilepsy and using polytherapy. In this ‘worst case
scenario’, the ABNAS-scores for the epilepsy group
were significantly higher than for the control group
of volunteers on placebo. However, there were no
significant differences between the scores of patients
on monotherapy or polytherapy, on different dosages,
or experiencing different levels of seizure frequency.
Thus providing further support for the hypothesis that
the ABNAS is a screening instrument, providing a
global subjective report of impairment. Overall, results
showed sufficient clinical sensitivity and excellent
reliability and validity.
Recently the psychometric properties of the scale
were analysed in detail, using specific techniques
such as MAP-R analyses11. Results obtained from
two populations: 200 patients with epilepsy and on
medication and 200 controls without medication,
showed that the ABNAS was not compromised by
general effects such as age or gender. Moreover,
the internal scales of the ABNAS showed excellent
psychometric properties. The difference in scoring
level between the controls and the patients with
epilepsy was significant with almost three times higher
scores for the patients with epilepsy.
So far one question remained unanswered. In
clinical practice often patient complaints have to be
interpreted, selecting those who need to be referred for
further neuropsychological assessment. A correlation
between the ABNAS-scores and neuropsychological
tests may provide the clinician with a helpful tool for
screening patients for further referral. Moreover, this
is an important step in validating the ABNAS-scores,
although correlations between patient complaints and
results of neuropsychological tests are generally
low in all kinds of clinical populations15, 17, 18.
Correlating the ABNAS with neuropsychological tests
is even more complex as patient perceived cognitive
impairment may be subjectively interpreted as drug-
related (thus leading to a higher ABNAS-score),
while the actual source may be different, e.g. seizure-
related. Nonetheless, we explored the relationships
between the ABNAS-scores and results of a set of
neuropsychological tests that has proven sensitivity for
cognitive effects of AEDs2, 5, 20.
METHOD
Trial design
We performed a clinical prospective comparative
study. The patients were equally selected from the
epilepsy outpatients clinic in the Walton Centre for
Neurology and Neurosurgery, Liverpool, UK and
from the Epilepsy Centre Kempenhaeghe, Heeze, The
Netherlands. To guarantee a sufficient variation in test
scores:
— About half the patients were selected from a
‘low risk condition’, i.e. patients on monother-
apy carbamazepine (CBZ). CBZ is a drug that
is considered to have only mild effects on
cognitive function when given within recom-
mended therapeutic doses2, 10, 19, 20. All patients
in this group had to be on steady-state treatment
with monotherapy CBZ within the dose-range
of 600–1200 mg/day for a minimum period of
4 months.
— About half the patients were selected from
a ‘high risk condition’. This could be: a
polytherapy of three AEDs of which two had
to be at clinical dose; or a combination therapy
including either phenytoin, phenobarbitone or
a benzodiazepine; or treatment with topiramate
with a titration speed using 50 mg or higher
increments per week and within the first
6 months of treatment3, 7, 12, 16, 19, 20.
All patients were prospectively assessed using psycho-
metric tests and the ABNAS.
Inclusion and exclusion criteria
Inclusion
Patients had to be >18 years, of normal intelligence
(established with the Wechsler Adult Intelligence
Scale), a reconfirmed diagnosis of epilepsy and
treatment with AEDs for a period of >4 months.
Exclusion
Patients were excluded on the basis of: a psychiatric
history or current psychiatric treatment; treatment with
other drugs than AEDs.
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The patients were included in 1999/2000 and
inclusion stopped after 40–50 patients were recruited
from each risk condition.
Consent
An independent ethics committee approved the study.
Subjects gave written informed consent before enter-
ing the study.
Instruments
(1) Cognitive tests
We used tests that have demonstrated sensitivity
for detecting cognitive side-effects of AEDs. This
selection was based on consensus meetings, e.g. the
workshop on measurement of drug-induced cognitive
impairment during the 21st International Epilepsy
Congress in Sydney5. All tests are part of the FePsy
computerized neuropsychological test battery and
are amply described elsewhere1, 2, 8, 9. The following
areas/tests were included:
(a) Psychomotor fluency
— ‘The finger tapping task’, measuring
motor speed and motor fluency in five
consecutive trials for the index finger
of the dominant hand (variable 1 is the
average number of taps for the dominant
hand).
(b) Cognitive activation/alertness and psychomotor
speed
— ‘Simple (visual) reaction-time measure-
ment’ on visual (a white square on
the screen) stimuli that are presented
at random intervals by the computer
(variable 2 is the average reaction-time in
milliseconds).
(c) Information processing speed
— ‘The binary choice reaction test’ in which
a decision component is introduced. The
subject has to react differentially to a red
square, presented on the left side of the
screen or to a green square, presented on
the right side. Reaction-time here reflects
not only motor speed but also the decision
making process (variable 3 is the average
reaction-time in milliseconds).
— ‘The computerized visual searching task’
(‘CVST’), an adaptation of Goldstein’s
‘visual searching task’. A centred grid
pattern has to be compared with 24
surrounding patterns, one of which is
identical to the target pattern. The test
consists of 24 trials and gives an indication
of the speed of information processing and
perceptual mental strategies (variable 4 is
the average reaction-time in seconds).
(d) Memory function
— ‘Recognition of words’. The test stimuli
are presented simultaneously during a
learning phase. Six words are presented
with a presentation time of 1 s per item.
After a delay of 2 s the screen shows one
of these words between distracters. The
target item has to be recognized (variable 5
is the number correct out of 24 trials)
(2) Patient perceived cognitive function
Subjects were given ABNAS, assessing subjectively
experienced side-effects. This scale is described
elsewhere4, 6, 11. From this test we only used the
overall score ranging from 0 (no side-effects reported
on any of the 24 items) to 72 (score of 3—severe
side-effects—on all 24 items). (Variable 6 is the total
ABNAS-score: 0–72.)
Variables 1–5 are the primary psychometric cogni-
tive variables. Variable 6 is the primary variable for
subjective cognitive experiences.
Statistical analysis
A sample size between 35 and 65 patients is
sufficient to detect medium-size behavioural effects
(i.e. changes of >0.5 standard deviation, following
Cohen’s conventions13, 14; see also reference 20) with
a significance level of 5% and a Beta of type-2
error risk (ß) of 20% (see the psychometric qualities
of the scale in Brooks et al., 2001). Medium-size
effects are generally seen as behavioural effects
of antiepileptics2, 20. We aimed at including >40
patients per ‘risk condition’ (see section on inclusion).
Therefore inclusion stopped after 40–50 patients were
included from each risk condition, resulting in a total
sample size between 80 and 100 patients. The results
were analysed using correlational analysis to compare
the psychometric results with the ABNAS-score, dis-
criminant analysis and cluster analysis to inspect the
possibility of using the ABNAS to screen patients. Sta-
tistical analysis was performed using SPSS/PC V9.1.
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Table 1: Demographic and clinical characteristics for the study population.
Number of patients 96
included from the ‘high risk condition’ 41
included from the ‘low risk condition’ 55
Age (mean years) 37.5 (10.8)
WAIS (Full scale IQ) 107.3 (13.4)
Gender Male 55
Female 41
Handedness Right 80.2%
Left 17.7%
No lateralization 2.1%
Type of epilepsy Localization related 70.8%
Idiopathic generalized 6.3%
Symptomatic generalized 4.2%
Cryptogenic generalized 1.0%
Not classified 17.7%
Seizure types Simple partial (n = 31) 13.9 p/month (23.0)
(and seizure frequency) Complex partial (n = 54) 6.8 p/month (8.2)
Secondary generalized seizures (n = 8) 8.3 p/ 12 year (8.2)
Absence seizures (n = 9) 12.4 p/month (15.3)
Myoclonic seizures (n = 1) 2.0 p/month (−)
SD given in parentheses.
RESULTS
Within the study period, 96 subjects met the inclusion
criteria, 55 from the ‘low risk condition’ (monotherapy
CBZ) and 41 from the ‘high risk condition’. None
of the subjects withdrew consent. Table 1 shows the
demographic and clinical characteristics for the study
population.
The majority of the patients had a localized-related
(partial) epilepsy with complex partial seizures, with
or without secondary generalization. The average
age was 37.5 years and there was no signifi-
cant difference with respect to gender (55 male,
41 female). The intelligence rating was average
(WAIS full scale IQ: 107; SD 13.4) and edu-
cational background ranged from lower secondary
education (31.7%) to higher forms of educa-
tion (7.3%). Intelligence was similar for the two
conditions (F: 1.008; P = 0.33). Medication was
monotherapy CBZ for the ‘low risk condition’
(average daily dose of 945 mg) and a high vari-
ability of medications and dosing for the ‘high
risk condition’ (see inclusion criteria). Differences
in distribution of seizure types between the two
selection-conditions (high risk/low risk condition)
were not statistically significant: simple partial
seizures: χ2 = 2.133, P = 0.144; complex partial
seizures: χ2 = 2.667, P = 0.102; secondary general-
ized seizures: χ2 = 2.000, P = 0.157. Patients in the
high risk condition had a higher seizure frequency for
simple partial seizures (P = 0.01) and for secondary
generalized seizures (P = 0.03).
Table 2 shows an average score on the ABNAS
scale of 19.46 for the total group (SD. 15.8), which
concurs with our results in a similar group with
chronic epilepsy (average ABNAS-score of 20.66)
and the epilepsy group in our recent study11. There is a
difference between the low risk and high risk condition
(18.64 vs. 20.56), but this difference is not statistically
significantly different (P = 0.55). The scores on the
neuropsychological tests are in accordance with scores
in a population with epilepsy1, 2, 8, 9.
Table 3 shows the results of the correlational
analysis between the results of the neuropsychological
tests and the ABNAS-score. Statistically significant
correlations are found for all tests except for the
‘the word recognition task’. The correlations for the
remaining four tasks are in the range of 0.22–0.35.
Highest correlation is with ‘simple (visual) reaction-
time measurement’ (0.35). The correlations are all
in the expected direction (for the three reaction-time
tasks a higher score on the ABNAS correlates with
slower reaction: for ‘the finger tapping task’ a higher
score on the ABNAS correlates with lower tapping
level and is thus negative).
Discriminant analysis was used to explore the
number of patients that can be correctly classified with
respect to their ABNAS-score, using the results on the
neuropsychological tests combined. This technique
thus uses the results of the neuropsychological tests
combined and inspects whether this correlates with
the ABNAS-score. To be able to perform discriminant
analysis (that uses a limited number of groups to
classify), the ABNAS-scores were dichotomized in
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Table 2: Scores for the ABNAS and the neuropsychological tests.
Score Mean values (standard deviation)
ABNAS-score for the total group 19.46 (15.8)
Comparison of the ABNAS-score for low vs. high risk condition:
—low risk condition: 18.64 (15.9)
—high risk condition: 20.56 (15.8)
∗t-test between high/low risk condition: t : −0.518 P = 0.55
Neuropsychological test scores
‘The finger tapping task’ (number of taps) 52.1 (8.7)
‘Simple (visual) reaction-time measurement’ (ms) 327.6 (118.1)
‘The binary choice reaction test’ (ms) 403.7 (157.2)
‘The CVST’ (s) 13.8 (5.8)
‘Recognition of words’ (number correct out of 24) 19.2 (9.0)
SD given in parentheses.
‘low scores’ (scores <15 n = 45) and ‘high scores’
(scores >15 n = 51). The cut-off point of 15 was
derived from the scores obtained in the control groups
in the studies2, 6, 11.
Using the scores of the neuropsychological tests
combined, 61.5% of the patients were correctly
identified as having high vs. low ABNAS-scores.
The classification table (Table 4) shows that the
neuropsychological tests sufficiently identify low
ABNAS-scores (82.2% of the low ABNAS-scores,
correctly identified) and a reasonable percentage of the
high scores (43.1%). A low score on the ABNAS is
thus associated with normal scores on the neuropsy-
chological impairments for the majority of the patients
(82.2%) and the ABNAS fails to identify impairment
in 17.8% of the patients (= low ABNAS-score but
subnormal scores on the neuropsychological tests). A
high score on the ABNAS is not always associated
with impairment on these neuropsychological tests.
Table 3: Results of the correlational analysis between the
ABNAS and the neuropsychological tests.
ABNAS-scorea
Correlation (R)
and P value (P)
‘The finger tapping task’ R = −0.24 (P = 0.01)
‘Simple (visual) reaction-time
measurement’ R = 0.35 (P = 0.001)
‘The binary choice reaction test’ R = 0.24 (P = 0.01)
‘The CVST R = 0.22 (P = 0.03)
‘Recognition of words’ R = 0.01 (P = 0.94)
aAll test correlations were statistically significant with the overall
ABNAS-score, except for recognition of words; SD given in
parentheses.
This latter finding concurs with the failure to show
statistically significant differences for the ABNAS-
score between patients included from a ‘low risk con-
dition’ (CBZ monotherapy) and the patients included
from a ‘high risk condition’ (polytherapy): see Table 2:
18.64 vs. 20.56 (P = 0.55). This does not necessarily
invalidate the ABNAS, as patients may in fact not have
cognitive side-effects, despite the ‘high risk’ condition
that they are exposed to. Vice versa, a monotherapy
of CBZ will normally not lead to negative cognitive
effects, but some patients will be an exception. Finally
for many patients it will be difficult to identify
the exact origin of the cognitive impairment. They
may subjectively experience cognitive difficulties and
associate these with the medication (and thus report
this on the ABNAS), although the actual cause may
be the epilepsy or the epileptic seizures. A patient
included from the ‘low risk condition’ of monotherapy
CBZ may, for example, have cognitive effects caused
by insufficient seizure control. Irrespective of the
cause, the result may be a high score on the ABNAS.
Table 4: Classification results of the discriminant analysis
predicting the ABNAS-scores with the results of the
neuropsychological tests.
Predicted group membership
(ABNAS-score based on the results of the neuropsychological tests)
Low score High score
Original Low score 82.2% 17.8%
(ABNAS-scores
in % low
or high scores) High score 56.9% 43.1%
61.5% of original grouped cases correctly classified.
Original: scores based on ABNAS, classified as high or low.
Predicted: scores on the ABNAS, predicted on the basis of the
neuropsychological tests.
As the aim of this study was to identify the
relationships between neuropsychological test perfor-
mance and the ABNAS-score, we rearranged ‘high
risk condition’ vs. ‘low risk condition’ using cluster
analysis, based on rank scores for the neuropsycholog-
ical tests combined. All subjects thus received a rank
score based on their scores on the neuropsychological
tests combined. In total, 21 of the 96 patients
236 A. P. Aldenkamp et al.
were replaced, based on their neuropsychological
scores and the new clusters were identified as ‘not
neuropsychologically impaired’ (n = 53) and ‘neu-
ropsychologically impaired’ (n = 43). The patients in
the ‘neuropsychologically impaired cluster’ are thus
patients that have the lowest scores on the combined
neuropsychological tests, irrespective of whether this
is caused by the medication or by other factors. After
this reclassification the ABNAS-scores are statistically
different (t-value −2.779 P = 0.007) as shown in
Table 5 with the highest ABNAS-score for the ‘neu-
ropsychologically impaired group’ (15.55 vs. 24.28).
Table 5: Difference of ABNAS-score between the groups with
lowest vs. the group with highest ranking on
neuropsychological tests.
Groups ABNAS-score t and P values
—‘Not neuropsychologically
impaired’ (lowest ranking on
the neuropsychological tests)
n = 53
15.55 (14.40) t-value −2.779;
P = 0.007
—‘Neuropsychologically
impaired’ (highest ranking on
the neuropsychological tests)
n = 43
24.28 (16.36)
SD given in parentheses.
DISCUSSION
This study contributes to the development of the
ABNAS, an instrument aimed at assessing patient-
perceived drug-related cognitive impairment. In this
study the outcome of a subjective report (total score
of the ABNAS) was compared with the results on
those neuropsychological tests that are generally used
to assess cognitive side-effects of AEDs. This is
a relevant phase in the validation process of an
instrument, given its use as a screening instrument.
The results can be used in the decision-making process
to refer a patient for further neuropsychological
evaluation.
Our results show modest but statistically sig-
nificant correlations between the ABNAS and the
neuropsychological tests, which is remarkable given
the absence of such correlations between subjective
measurements and results of tests in a number of
other clinical conditions15, 17, 18. Our study analysed
correlations in 96 patients with reconfirmed epilepsy,
included from two different conditions: a ‘low risk
condition’ (monotherapy CBZ) and a ‘high risk
condition’ (basically polytherapy). This inclusion
procedure aimed at achieving sufficient variations of
scores in the study sample. Statistically significant
correlations between the overall ABNAS-score and
the neuropsychological tests were found for all ‘speed
tests’: ‘simple (visual) reaction-time measurement’,
‘binary choice reaction-time measurement’ and the
‘visual searching task’ (CVST); all three using
reaction-time as the primary outcome and ‘the
finger tapping task’ (motor speed and fluency), with
correlations ranging from 0.22 to 0.35. The highest
correlation was with ‘simple (visual) reaction-time
measurement’ (0.35). This is in line with findings of
neuropsychological studies that consistently identify
‘speed factors’ as the most sensitive area in relation
to drug treatment16, 19, 20, specifically psychomotor
speed that is primarily measured with ‘simple (visual)
reaction-time measurement’. The correlations were all
in the expected direction (for the three reaction-time
tasks a higher score on the ABNAS correlates with
slower reaction-time, for the finger tapping task a
higher score on the ABNAS correlates with lower
tapping level). The memory test was not correlated
with the ABNAS-score.
Although statistically significant, most correlations
are relatively modest (0.35 at maximum), which
indicates that other factors have a strong impact on the
ABNAS-scores: the epilepsy and its underlying aetiol-
ogy or the seizures. This concurs with the absence of
a significant difference in ABNAS-scores between the
two groups included in this study: ‘high risk condition’
and ‘low risk condition’. A score of a patient in the
‘low risk condition’ may nevertheless be high because
other factors are involved with potential effect on
cognitive function, such as the effect of insufficiently
controlled seizures. The ABNAS provides a subjective
score: the patient reports cognitive impairment and
although he/she infers that this is a drug-induced effect
(which is an important sign in clinical practice), it
may be impossible for the patient to separate drug-
induced effects from other sources inducing cognitive
impairment. This is even more complicated as these
factors often occur in the same period: when seizure
frequency increases, this is often followed by drug
changes and when cognitive impairments develop in
this period, both the increase of seizure frequency
and the drug changes could be responsible for the
cognitive impairments. Whatever source, an important
aspect of the validity of the ABNAS is that a high
score indicates neuropsychological difficulties. When
the patients were classified on the basis of ranks on
the neuropsychological tests, the ABNAS-score was
statistically significantly different, with a 60% higher
score for the patients with lowest neuropsychological
ranks (15.55 vs. 24.28).
This was also demonstrated with a classification
analysis technique: discriminant analysis. Using the
neuropsychological tests combined 61.5% of the
patients were correctly identified as having high or low
ABNAS-scores. Important for clinical practice is that
a low ABNAS-score correctly identifies the absence
of neuropsychological impairment as measured by the
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neuropsychological tests (82.2% of the low ABNAS-
scores are associated with normal neuropsychological
scores). A low score on the ABNAS will thus fail to
identify actual neuropsychological impairment only in
17.8% of the patients.
When we now combine the results of the four
studies that we performed with the ABNAS4, 6, 11,
the present study, we may conclude that the ABNAS
has validity as a screening instrument for both
clinical practice and for drug trials with sufficient
reliability, sensitivity for change and internal consis-
tency. Moreover we now have established that the
ABNAS is sufficiently related with the outcomes of
both neuropsychological assessment with the FePsy
computerized test battery (present study) and the
results of mood rating scales11, to be used for
screening patients who are at risk of drug-induced
behavioural impairment. Moreover, the correlation
between ABNAS-score and those neuropsychological
tests that are sensitive for drug-effects may provide a
sensitive instrument in early drug-development phases
while keeping the burden on financial and time
resources to a minimum.
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